Lucintel Forecasts the Lung Cancer Surgery Market in United States to Reach $6 Billion by 2031

According to a market report by Lucintel, the future of the lung cancer surgery market in United States looks promising with opportunities in the hospital, specialty cancer care center, and ambulatory surgical center markets. The lung cancer surgery market in United States is expected to reach an estimated $6 billion by 2031 with a CAGR of 3.4% from 2025 to 2031. The major drivers for this market are the rising occurrence of lung cancer, the increasing consumer preference towards minimally invasive surgeries, and the growing air pollution levels.

A more than 150-page report to understand trends, opportunity and forecast in lung cancer surgery market in United States to 2031 by product type (surgical devices, endosurgical equipment, and monitoring or visualizing equipment), surgery (robotic surgery, thoracotomy, video assisted surgery, percutaneous surgery, and endobronchial surgery), and end use (hospitals, specialty cancer care centers, ambulatory surgical centers, and others).

Download sample by clicking on lung cancer surgery market in United States.

Lucintel forecasts that, within the product type category, surgical device is expected to witness the highest growth over the forecast period.

Within the end use category, ambulatory surgical center is expected to witness the highest growth over the forecast period.

This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at helpdesk@lucintel.com. To get access of more than 1000 reports at fraction of cost visit Lucintel's Analytics Dashboard.

About Lucintel

At Lucintel, we offer solutions for you growth through game changer ideas and robust market & unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times.

Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1-972-636-5056

Explore Our Latest Publications

Lung Cancer Surgery Market in Australia

Lung Cancer Surgery Market in Brazil

Lung Cancer Surgery Market in Canada

Lung Cancer Surgery Market in Mexico

Lung Cancer Surgery Market in Saudi Arabia

Lung Cancer Surgery Market in South Africa

 

Lucintel Forecasts the Lung Cancer Surgery Market in Japan to Reach $6 Billion by 2031

According to a market report by Lucintel, the future of the lung cancer surgery market in Japan looks promising with opportunities in the hospital, specialty cancer care center, and ambulatory surgical center markets. The lung cancer surgery market in Japan is expected to reach an estimated $6 billion by 2031 with a CAGR of 3.4% from 2025 to 2031. The major drivers for this market are the rising occurrence of lung cancer, the increasing consumer preference towards minimally invasive surgeries, and the growing air pollution levels.

A more than 150-page report to understand trends, opportunity and forecast in lung cancer surgery market in Japan to 2031 by product type (surgical devices, endosurgical equipment, and monitoring or visualizing equipment), surgery (robotic surgery, thoracotomy, video assisted surgery, percutaneous surgery, and endobronchial surgery), and end use (hospitals, specialty cancer care centers, ambulatory surgical centers, and others).

Download sample by clicking on lung cancer surgery market in Japan.

Lucintel forecasts that, within the product type category, surgical device is expected to witness the highest growth over the forecast period.

Within the end use category, ambulatory surgical center is expected to witness the highest growth over the forecast period.

This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at helpdesk@lucintel.com. To get access of more than 1000 reports at fraction of cost visit Lucintel's Analytics Dashboard.

About Lucintel

At Lucintel, we offer solutions for you growth through game changer ideas and robust market & unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times.

Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1-972-636-5056

Explore Our Latest Publications

Lung Cancer Surgery Market in India

Lung Cancer Surgery Market in Indonesia

Lung Cancer Surgery Market in Malaysia

Lung Cancer Surgery Market in China

Lung Cancer Surgery Market in South Korea

Lung Cancer Surgery Market in Thailand

Lucintel Forecasts the Lung Cancer Surgery Market in Germany to Reach $6 Billion by 2031

According to a market report by Lucintel, the future of the lung cancer surgery market in Germany looks promising with opportunities in the hospital, specialty cancer care center, and ambulatory surgical center markets. The lung cancer surgery market in Germany is expected to reach an estimated $6 billion by 2031 with a CAGR of 3.4% from 2025 to 2031. The major drivers for this market are the rising occurrence of lung cancer, the increasing consumer preference towards minimally invasive surgeries, and the growing air pollution levels.

A more than 150-page report to understand trends, opportunity and forecast in lung cancer surgery market in Germany to 2031 by product type (surgical devices, endosurgical equipment, and monitoring or visualizing equipment), surgery (robotic surgery, thoracotomy, video assisted surgery, percutaneous surgery, and endobronchial surgery), and end use (hospitals, specialty cancer care centers, ambulatory surgical centers, and others).

Download sample by clicking on lung cancer surgery market in Germany.

Lucintel forecasts that, within the product type category, surgical device is expected to witness the highest growth over the forecast period.

Within the end use category, ambulatory surgical center is expected to witness the highest growth over the forecast period.

This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at helpdesk@lucintel.com. To get access of more than 1000 reports at fraction of cost visit Lucintel's Analytics Dashboard.

About Lucintel

At Lucintel, we offer solutions for you growth through game changer ideas and robust market & unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times.

Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1-972-636-5056

Explore Our Latest Publications

Lung Cancer Surgery Market in Italy

Lung Cancer Surgery Market in Netherlands

Lung Cancer Surgery Market in Spain

Lung Cancer Surgery Market in Turkey

Lung Cancer Surgery Market in United Kingdom

Lucintel Forecasts the Klebsiella Pneumoniae Infection Market in United States to Grow with a CAGR of 4.5% from 2025 to 2031

According to a market report by Lucintel, the future of the Klebsiella Pneumoniae Infection Market in United States looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets. The Klebsiella Pneumoniae Infection Market in United States is expected to grow with a CAGR of 4.5% from 2025 to 2031. The major drivers for this market are the increasing occurrence of antibiotic-resistant Klebsiella pneumoniae strains, the broad implementation of strict hospital hygiene guidelines and infection control measures, and the growing efforts in researching novel treatments for Klebsiella pneumoniae infection.

A more than 150-page report to understand trends, opportunity and forecast in Klebsiella Pneumoniae Infection Market in United States to 2031 by infection type (pneumonia, urinary tract infections, bloodstream infections, intra-abdominal infections, and wound infections), drug class (beta-lactams, aminoglycoside, quinolones, cephalosporins, and carbapenems), and distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies).

Download sample by clicking on Klebsiella Pneumoniae Infection Market in United States.

Lucintel forecasts that, within the drug class category, beta-lactams is expected to witness the highest growth over the forecast period.

Within the distribution channel category, hospital pharmacy is expected to witness the highest growth.

This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at helpdesk@lucintel.com. To get access of more than 1000 reports at fraction of cost visit Lucintel's Analytics Dashboard.

About Lucintel

At Lucintel, we offer solutions for you growth through game changer ideas and robust market & unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times.

Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1-972-636-5056

Explore Our Latest Publications

Klebsiella Pneumoniae Infection Market in Australia

Klebsiella Pneumoniae Infection Market in Brazil

Klebsiella Pneumoniae Infection Market in Canada

Klebsiella Pneumoniae Infection Market in Mexico

Klebsiella Pneumoniae Infection Market in Saudi Arabia

Klebsiella Pneumoniae Infection Market in South Africa

Lucintel Forecasts the Klebsiella Pneumoniae Infection Market in Japan to Grow with a CAGR of 4.5% from 2025 to 2031

According to a market report by Lucintel, the future of the Klebsiella Pneumoniae Infection Market in Japan looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets. The Klebsiella Pneumoniae Infection Market in Japan is expected to grow with a CAGR of 4.5% from 2025 to 2031. The major drivers for this market are the increasing occurrence of antibiotic-resistant Klebsiella pneumoniae strains, the broad implementation of strict hospital hygiene guidelines and infection control measures, and the growing efforts in researching novel treatments for Klebsiella pneumoniae infection.

A more than 150-page report to understand trends, opportunity and forecast in Klebsiella Pneumoniae Infection Market in Japan to 2031 by infection type (pneumonia, urinary tract infections, bloodstream infections, intra-abdominal infections, and wound infections), drug class (beta-lactams, aminoglycoside, quinolones, cephalosporins, and carbapenems), and distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies).

Download sample by clicking on Klebsiella Pneumoniae Infection Market in Japan.

Lucintel forecasts that, within the drug class category, beta-lactams is expected to witness the highest growth over the forecast period.

Within the distribution channel category, hospital pharmacy is expected to witness the highest growth.

This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at helpdesk@lucintel.com. To get access of more than 1000 reports at fraction of cost visit Lucintel's Analytics Dashboard.

About Lucintel

At Lucintel, we offer solutions for you growth through game changer ideas and robust market & unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times.

Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1-972-636-5056

Explore Our Latest Publications

Klebsiella Pneumoniae Infection Market in India

Klebsiella Pneumoniae Infection Market in Indonesia

Klebsiella Pneumoniae Infection Market in Malaysia

Klebsiella Pneumoniae Infection Market in China

Klebsiella Pneumoniae Infection Market in South Korea

Klebsiella Pneumoniae Infection Market in Thailand

 

Lucintel Forecasts the Klebsiella Pneumoniae Infection Market in Germany to Grow with a CAGR of 4.5% from 2025 to 2031

According to a market report by Lucintel, the future of the Klebsiella Pneumoniae Infection Market in Germany looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets. The Klebsiella Pneumoniae Infection Market in Germany is expected to grow with a CAGR of 4.5% from 2025 to 2031. The major drivers for this market are the increasing occurrence of antibiotic-resistant Klebsiella pneumoniae strains, the broad implementation of strict hospital hygiene guidelines and infection control measures, and the growing efforts in researching novel treatments for Klebsiella pneumoniae infection.

A more than 150-page report to understand trends, opportunity and forecast in Klebsiella Pneumoniae Infection Market in Germany to 2031 by infection type (pneumonia, urinary tract infections, bloodstream infections, intra-abdominal infections, and wound infections), drug class (beta-lactams, aminoglycoside, quinolones, cephalosporins, and carbapenems), and distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies).

Download sample by clicking on Klebsiella Pneumoniae Infection Market in Germany.

Lucintel forecasts that, within the drug class category, beta-lactams is expected to witness the highest growth over the forecast period.

Within the distribution channel category, hospital pharmacy is expected to witness the highest growth.

This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at helpdesk@lucintel.com. To get access of more than 1000 reports at fraction of cost visit Lucintel's Analytics Dashboard.

About Lucintel

At Lucintel, we offer solutions for you growth through game changer ideas and robust market & unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times.

Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1-972-636-5056

Explore Our Latest Publications

Klebsiella Pneumoniae Infection Market in Italy

Klebsiella Pneumoniae Infection Market in Netherlands

Klebsiella Pneumoniae Infection Market in Spain

Klebsiella Pneumoniae Infection Market in Turkey

Klebsiella Pneumoniae Infection Market in United Kingdom

Lucintel Forecasts the Hyperthermia Cancer Treatment Market in United States to Reach $264 Million by 2031

According to a market report by Lucintel, the future of the hyperthermia cancer treatment market in United States looks promising with opportunities in the breast cancer, liver cancer, soft tissue sarcoma, head & neck tumor, and prostate cancer markets. The hyperthermia cancer treatment market in United States is expected to reach an estimated $264 million by 2031 with a CAGR of 5.8% from 2025 to 2031. The major drivers for this market are the increasing incidence of cancer worldwide, the growing awareness and acceptance of non-invasive cancer therapies, and the rising popularity of nanoparticle-mediated hyperthermia.

A more than 150-page report to understand trends, opportunity and forecast in hyperthermia cancer treatment market in United States to 2031 by type (local hyperthermia system and whole body hyperthermia system), and application (breast cancer, liver cancer, soft tissue sarcoma, head & neck tumors, prostate cancer, and others).

Download sample by clicking on hyperthermia cancer treatment market in United States.

Lucintel forecasts that, within the type category, the local hyperthermia system is expected to witness higher growth over the forecast period.

Within the application category, breast cancer is expected to witness the highest growth over the forecast period.

This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at helpdesk@lucintel.com. To get access of more than 1000 reports at fraction of cost visit Lucintel's Analytics Dashboard.

About Lucintel

At Lucintel, we offer solutions for you growth through game changer ideas and robust market & unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times.

Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1-972-636-5056

Explore Our Latest Publications

Hyperthermia Cancer Treatment Market in Australia

Hyperthermia Cancer Treatment Market in Brazil

Hyperthermia Cancer Treatment Market in Canada

Hyperthermia Cancer Treatment Market in Mexico

Hyperthermia Cancer Treatment Market in Saudi Arabia

Hyperthermia Cancer Treatment Market in South Africa

Lucintel Forecasts the Hyperthermia Cancer Treatment Market in Japan to Reach $264 Million by 2031

According to a market report by Lucintel, the future of the hyperthermia cancer treatment market in Japan looks promising with opportunities in the breast cancer, liver cancer, soft tissue sarcoma, head & neck tumor, and prostate cancer markets. The hyperthermia cancer treatment market in Japan is expected to reach an estimated $264 million by 2031 with a CAGR of 5.8% from 2025 to 2031. The major drivers for this market are the increasing incidence of cancer worldwide, the growing awareness and acceptance of non-invasive cancer therapies, and the rising popularity of nanoparticle-mediated hyperthermia.

A more than 150-page report to understand trends, opportunity and forecast in hyperthermia cancer treatment market in Japan to 2031 by type (local hyperthermia system and whole body hyperthermia system), and application (breast cancer, liver cancer, soft tissue sarcoma, head & neck tumors, prostate cancer, and others).

Download sample by clicking on hyperthermia cancer treatment market in Japan.

Lucintel forecasts that, within the type category, the local hyperthermia system is expected to witness higher growth over the forecast period.

Within the application category, breast cancer is expected to witness the highest growth over the forecast period.

This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at helpdesk@lucintel.com. To get access of more than 1000 reports at fraction of cost visit Lucintel's Analytics Dashboard.

About Lucintel

At Lucintel, we offer solutions for you growth through game changer ideas and robust market & unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times.

Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1-972-636-5056

Explore Our Latest Publications

Hyperthermia Cancer Treatment Market in India

Hyperthermia Cancer Treatment Market in Indonesia

Hyperthermia Cancer Treatment Market in Malaysia

Hyperthermia Cancer Treatment Market in China

Hyperthermia Cancer Treatment Market in South Korea

Hyperthermia Cancer Treatment Market in Thailand

 

Lucintel Forecasts the Hyperthermia Cancer Treatment Market in Germany to Reach $264 Million by 2031

According to a market report by Lucintel, the future of the hyperthermia cancer treatment market in Germany looks promising with opportunities in the breast cancer, liver cancer, soft tissue sarcoma, head & neck tumor, and prostate cancer markets. The hyperthermia cancer treatment market in Germany is expected to reach an estimated $264 million by 2031 with a CAGR of 5.8% from 2025 to 2031. The major drivers for this market are the increasing incidence of cancer worldwide, the growing awareness and acceptance of non-invasive cancer therapies, and the rising popularity of nanoparticle-mediated hyperthermia.

A more than 150-page report to understand trends, opportunity and forecast in hyperthermia cancer treatment market in Germany to 2031 by type (local hyperthermia system and whole body hyperthermia system), and application (breast cancer, liver cancer, soft tissue sarcoma, head & neck tumors, prostate cancer, and others).

Download sample by clicking on hyperthermia cancer treatment market in Germany.

Lucintel forecasts that, within the type category, the local hyperthermia system is expected to witness higher growth over the forecast period.

Within the application category, breast cancer is expected to witness the highest growth over the forecast period.

This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at helpdesk@lucintel.com. To get access of more than 1000 reports at fraction of cost visit Lucintel's Analytics Dashboard.

About Lucintel

At Lucintel, we offer solutions for you growth through game changer ideas and robust market & unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times.

Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1-972-636-5056

Explore Our Latest Publications

Hyperthermia Cancer Treatment Market in Italy

Hyperthermia Cancer Treatment Market in Netherlands

Hyperthermia Cancer Treatment Market in Spain

Hyperthermia Cancer Treatment Market in Turkey

Hyperthermia Cancer Treatment Market in United Kingdom

Lucintel Forecasts the Cervical Dysplasia Treatment Market in United States to Reach $839 Million by 2031

According to a market report by Lucintel, the future of the cervical dysplasia treatment market in United States looks promising with opportunities in the hospital, ambulatory surgery center, and specialty clinic markets. The cervical dysplasia treatment market in United States is expected to reach an estimated $839 million by 2031 with a CAGR of 4.4% from 2025 to 2031. The major drivers for this market are the rising rates of human papillomavirus infection, the increased awareness and advocacy for women‘s health issues encourage regular screenings, and the advancement in diagnostic methods such as HPV testing and colposcopy.

A more than 150-page report to understand trends, opportunity and forecast in cervical dysplasia treatment market in United States to 2031 by treatment (cervical dysplasia surgery, cervical dysplasia cryosurgery, cervical dysplasia leep, cervical dysplasia radiation therapy, cervical dysplasia chemotherapy, and others), and end use (hospitals, ambulatory surgery centers, specialty clinics, and others).

Download sample by clicking on cervical dysplasia treatment market in United States.

Lucintel forecasts that, within the treatment category, cervical dysplasia LEEP is expected to witness the highest growth over the forecast period due to it is a minimally invasive surgical procedure that is usually preferred for the treatment of cervical dysplasia.

Within the end use category, specialty clinic is expected to witness the highest growth due to the availability of healthcare professionals with specialized training and understanding in cervical dysplasia management can be found in specialty clinics.

This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at helpdesk@lucintel.com. To get access of more than 1000 reports at fraction of cost visit Lucintel's Analytics Dashboard.

About Lucintel

At Lucintel, we offer solutions for you growth through game changer ideas and robust market & unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times.

Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1-972-636-5056

Explore Our Latest Publications

Cervical Dysplasia Treatment Market in Australia

Cervical Dysplasia Treatment Market in Brazil

Cervical Dysplasia Treatment Market in Canada

Cervical Dysplasia Treatment Market in Mexico

Cervical Dysplasia Treatment Market in Saudi Arabia

Cervical Dysplasia Treatment Market in South Africa